Curi Bio and Cook MyoSite Form Strategic Partnership to Advance Muscle and Metabolic Disease Research
Thursday, May 01, 2025
Curi Bio, a global provider of human 3D engineered tissue platforms, has entered into a strategic partnership with Cook MyoSite, a company specialising in skeletal muscle-based therapies. The collaboration aims to develop advanced human tissue models to support research into muscle-related diseases and metabolic disorders such as obesity and diabetes.
As part of the partnership, Curi Bio will apply its Mantarray 3D tissue engineering system in combination with primary human myoblasts and fibro-adipogenic progenitor cells (FAPs) supplied by Cook MyoSite. This integration is expected to produce tissue models that closely reflect human physiology and provide more accurate insights into diseases including sarcopenia, neuromuscular disorders, and conditions treated with GLP-1-based therapies.
The new models aim to overcome limitations found in traditional two-dimensional (2D) systems and animal studies. By replicating human tissue more effectively, they offer the potential for more reliable preclinical testing and improved understanding of disease mechanisms.
Cook MyoSite brings more than 20 years of experience in the use of human primary skeletal muscle cells, supported by a large donor tissue bank. Combined with Curi Bio’s engineering expertise, the partnership is expected to offer improved platforms for drug screening and disease modelling.
The advanced tissue models developed through this collaboration are now commercially available. Key benefits include:
- Access to translational data not typically achievable using animal models or standard 2D myoblast systems
- Faster drug discovery by identifying potential issues earlier in the development process
- Deeper insight into metabolic and muscle-related diseases, helping to support the development of new treatments
This partnership positions both companies as leaders in next-generation tissue modelling, supporting scientific progress in the treatment of metabolic and muscle-related conditions.
Source: curibio.com
